The innovative drug market in our country is accelerating its explosion.

In the first half of this year, 38 "global new" innovative drugs from China were approved. Meanwhile, the total value of innovative drug licensing transactions abroad reached approximately $110 billion, accounting for 80% of the total expected for the entire year of 2025, setting a new historical high for the same period. From the approval of the world's first CAR-T cell drug for solid tumors to the historical high in overseas licensing transaction amounts for innovative drugs, Chinese innovative drugs are entering a new stage of development. Data shows that as of the end of June, the National Medical Products Administration has approved a total of 2,318 drug registration applications this year, which includes 38 "global new" innovative drugs. In the first half of this year, the total amount of domestic innovative drug licensing transactions abroad reached about $110 billion, already accounting for 80% of the total expected for 2025. Moving from "following" to "running alongside," and from individual products to capabilities across the entire industry chain, Chinese innovative drugs are accelerating their journey to the world. Taking an innovative drug from the laboratory to the market requires not only source innovation but also the ability for large-scale, low-cost manufacturing. Today, artificial intelligence has become deeply embedded in the drug development process. At the National Key Laboratory for Neuro and Oncology Drug Development in Shanghai, AI is assisting researchers in reducing trial-and-error costs, from target discovery and molecular design to activity prediction and toxicological assessment. R&D personnel from companies noted that generating 1,000 small molecules used to take about 10 days in the past, but now, with the aid of AI-assisted drug design platforms, it takes just about 2 minutes, increasing the screening efficiency nearly 30 times. If laboratory innovation is the source of new drug births, then large-scale, low-cost manufacturing is the "last mile" that makes innovative drugs accessible to patients. As industry insiders say, Chinese innovative drugs are transitioning from being followers in global innovation to co-builders who can stand shoulder to shoulder with top pharmaceutical companies worldwide.